HER2 Support Group Forums - View Single Post - Gemcitabine and Oxaliplatin

eric · 01-03-2007, 06:57 PM

http://content.karger.com/ProdukteDB...tentOnly=falseSalvage Chemotherapy with Gemcitabine and Oxaliplatin in Heavily Pretreated Patients with Metastatic Breast Cancer: A Multicenter Phase II Study
S. Kakolyrisa, K. Kalbakisb, A. Potamianouc, N. Malamosd, L. Vamvakasb, C. Christophillakise, E. Tselepatiotisf, S. Giassasb, D. Mavrousisb, K. Amarantidisa, V. Georgouliasb

aDepartment of Medical Oncology, University General Hospital, Alexandroupolis,
bDepartment of Medical Oncology, University General Hospital, Heraklion,
cDepartment of Medical Oncology, Metaxas Anticancer Hospital, Pireas,
dDepartment of Medical Oncology, M. Hliadis Hospital,
eDepartment of Medical Oncology, 401 Military Hospital, and
fDepartment of Internal Medicine, Patision General Hospital, Athens, Greece

Address of Corresponding Author

Oncology 2006;70:273-279 (DOI: 10.1159/000096248)

Key Words

Oxalipatin
Gemcitabine
Metastatic breast cancer

Abstract

Purpose: It was the aim of this study to evaluate the activity and tolerance of gemcitabine and oxaliplatin in pretreated metastatic breast cancer patients. Methods: Thirty-one patients who had disease relapse or progression after completion of an anthracycline- and/or taxane-based front-line regimen were treated with gemcitabine 1,500 mg/m2 on days 1 and 8 as a 30-min intravenous infusion and oxaliplatin 130 mg/m2 on day 8 as a 4-hour intravenous infusion, in cycles of 21 days. Results: Complete response occurred in 1 patient (3%) and partial response in 4 patients (13%) (overall response rate 16%; 95% confidence interval 3.2-29.1). Nine patients (29%) had stable disease and 17 (55%) progressive disease. Three partial responses (13%) were achieved among 23 patients receiving the regimen as third-line treatment. The median duration of response was 6 months (range 3-44.8), the median time to tumor progression 4.6 months (range 0.8-43.8), and the median survival 14.4 months (range 2.1-44.8). Grade 3 and 4 neutropenia occurred in 14 patients (45%), grade 3 and 4 thrombocytopenia in 6 patients (20%), and grade 2 and 3 asthenia in 4 patients (13%). There was no episode of febrile neutropenia. Conclusion: The gemcitabine-oxaliplatin combination is a relatively active and well-tolerated salvage regimen in patients with heavily pretreated metastatic breast cancer.

Copyright © 2006 S. Karger AG, Basel

Author Contacts

Prof. Vassilis Georgoulias, MD, PhD
University General Hospital of Heraklion
Department of Medical Oncology, Voutes, PO Box 1352
GR-71110 Heraklion, Crete (Greece)
Tel. +30 2810 392 747, Fax +30 2810 392 802, E-Mail georgoul@med.uoc.gr

01-03-2007, 06:57 PM	#1
eric Senior Member Join Date: Sep 2005 Posts: 589	Gemcitabine and Oxaliplatin - Greece http://content.karger.com/ProdukteDB...tentOnly=falseSalvage Chemotherapy with Gemcitabine and Oxaliplatin in Heavily Pretreated Patients with Metastatic Breast Cancer: A Multicenter Phase II Study S. Kakolyrisa, K. Kalbakisb, A. Potamianouc, N. Malamosd, L. Vamvakasb, C. Christophillakise, E. Tselepatiotisf, S. Giassasb, D. Mavrousisb, K. Amarantidisa, V. Georgouliasb aDepartment of Medical Oncology, University General Hospital, Alexandroupolis, bDepartment of Medical Oncology, University General Hospital, Heraklion, cDepartment of Medical Oncology, Metaxas Anticancer Hospital, Pireas, dDepartment of Medical Oncology, M. Hliadis Hospital, eDepartment of Medical Oncology, 401 Military Hospital, and fDepartment of Internal Medicine, Patision General Hospital, Athens, Greece Address of Corresponding Author Oncology 2006;70:273-279 (DOI: 10.1159/000096248) Key Words Oxalipatin Gemcitabine Metastatic breast cancer Abstract Purpose: It was the aim of this study to evaluate the activity and tolerance of gemcitabine and oxaliplatin in pretreated metastatic breast cancer patients. Methods: Thirty-one patients who had disease relapse or progression after completion of an anthracycline- and/or taxane-based front-line regimen were treated with gemcitabine 1,500 mg/m2 on days 1 and 8 as a 30-min intravenous infusion and oxaliplatin 130 mg/m2 on day 8 as a 4-hour intravenous infusion, in cycles of 21 days. Results: Complete response occurred in 1 patient (3%) and partial response in 4 patients (13%) (overall response rate 16%; 95% confidence interval 3.2-29.1). Nine patients (29%) had stable disease and 17 (55%) progressive disease. Three partial responses (13%) were achieved among 23 patients receiving the regimen as third-line treatment. The median duration of response was 6 months (range 3-44.8), the median time to tumor progression 4.6 months (range 0.8-43.8), and the median survival 14.4 months (range 2.1-44.8). Grade 3 and 4 neutropenia occurred in 14 patients (45%), grade 3 and 4 thrombocytopenia in 6 patients (20%), and grade 2 and 3 asthenia in 4 patients (13%). There was no episode of febrile neutropenia. Conclusion: The gemcitabine-oxaliplatin combination is a relatively active and well-tolerated salvage regimen in patients with heavily pretreated metastatic breast cancer. Copyright © 2006 S. Karger AG, Basel Author Contacts Prof. Vassilis Georgoulias, MD, PhD University General Hospital of Heraklion Department of Medical Oncology, Voutes, PO Box 1352 GR-71110 Heraklion, Crete (Greece) Tel. +30 2810 392 747, Fax +30 2810 392 802, E-Mail georgoul@med.uoc.gr